Articles Tagged With: apixaban
-
Apixaban Dose in Atrial Fibrillation Patients with Chronic Kidney Disease
A large nationwide health systems database study comparing 5 mg apixaban vs. 2.5 mg twice daily in patients with stage 4/5 chronic kidney disease not on dialysis shows that the 5 mg dose increases the risk of bleeding compared to 2.5 mg without any improvement in the risk of stroke, systemic emboli, or death.
-
Apixaban vs. Aspirin for Subclinical Atrial Fibrillation
A randomized controlled trial of apixaban vs. low-dose aspirin therapy for subclinical atrial fibrillation detected by implanted electrophysiologic devices showed that apixaban is associated with fewer strokes, but more major bleeding episodes compared to aspirin.
-
Apixaban Dose in Atrial Fibrillation Patients with Chronic Kidney Disease
A large nationwide health systems database study comparing 5 mg apixaban vs. 2.5 mg twice daily in patients with stage 4/5 chronic kidney disease not on dialysis shows that the 5 mg dose increases the risk of bleeding compared to 2.5 mg without any improvement in the risk of stroke, systemic emboli, or death.
-
Apixaban Had Lower Risk of GI Bleed than Other Oral Anticoagulants in Patients with Atrial Fibrillation
In this multinational, population-based cohort study among patients with atrial fibrillation, apixaban use was associated with lower risk of gastrointestinal bleeding with similar rates of ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality.
-
Apixaban for Venous Thromboembolism in Patients with End-Stage Kidney Disease
There is a lower risk of bleeding for those taking apixaban during venous thromboembolism treatment compared to warfarin in patients with end-stage kidney disease.
-
Simplifying Anticoagulation: Apixaban for VTE in Patients with End-Stage Kidney Disease
There is a lower risk of bleeding with apixaban during the treatment of venous thromboembolism compared to warfarin in patients with end-stage kidney disease.
-
Pharmacotherapy for Atrial Fibrillation with Anticoagulation-Associated Intracranial Hemorrhage
A study of apixaban vs. no anticoagulation in patients following an anticoagulant for atrial fibrillation-related intracerebral hemorrhage exhibited a high risk of stroke and vascular death, regardless of whether the patients were treated subsequently with apixaban.
-
Reversal of Direct Oral Anticoagulants
Given the growing use of direct oral anticoagulants, particularly in the elderly population, it is important as an emergency physician to be well versed on the methods of emergent reversal of these agents in the bleeding patient.
-
Optimal Antithrombic Therapy After PCI for Atrial Fibrillation Patients
In three subgroups of coronary artery disease patients with atrial fibrillation, apixaban plus a P2Y12 inhibitor provided superior safety and similar efficacy outcomes as treatment with warfarin, aspirin, or both for six months.
-
Optimal Antithrombic Therapy After PCI for Atrial Fibrillation Patients
In three subgroups of coronary artery disease patients with atrial fibrillation, apixaban plus a P2Y12 inhibitor provided superior safety and similar efficacy outcomes as treatment with warfarin, aspirin, or both for six months.